License Revenue, Agreements and Strategic Investment - Additional Information (Details) - USD ($)	1 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Aug. 31, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items]
Compound library and option agreement execution month and year			2016-02
Common stock, shares issued			62,991,906	53,253,213
Common stock, value			$ 6,000	$ 5,000
Licensed Products
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalties due from sales			0
License Agreement | Jocasta Neuroscience, Inc.
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront cash payments received			5,000,000.0
Revenue recognized			4,800,000	0
Deferred revenue			200,000
Other Licensing Agreements with Research Institutions
Research And Development Arrangement Contract To Perform For Others [Line Items]
Contingent consideration, milestone or royalty payments			0	$ 0
Other Licensing Agreements with Research Institutions | UCSF
Research And Development Arrangement Contract To Perform For Others [Line Items]
Common shares expected to be issued		34,000
Contingent consideration, milestone or royalty payments			$ 0
Maximum milestone payments for each product licensed under agreement		$ 13,600,000
Other Licensing Agreements with Research Institutions | UCSF | Common Stock
Research And Development Arrangement Contract To Perform For Others [Line Items]
Issuance of common stock		120,000
Other Licensing Agreements with Research Institutions | UCSF | Additional Paid-In Capital
Research And Development Arrangement Contract To Perform For Others [Line Items]
Common stock issued to third parties		$ 1,000,000.0
Commercial Agreement | Clinical Stage Biopharmaceutical Company
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments	$ 2,000,000.0
Equity payments percentage			80.00%
Common stock, shares issued			1,269,755	361,664	294,775
Common stock fair market value, net of withholding taxes					$ 1,100,000
Common stock, value				$ 2,300,000
Contingent consideration liability			$ 0
Strategic investments			0	0
Change in fair value of investment			$ 0	$ 500,000
Funding provided for the research and development under the agreement in period			2020-02
Commercial Agreement | Clinical Stage Biopharmaceutical Company | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Contingent consideration additional common stock issued for one licensed product			933,337
Contingent consideration additional common stock issued for two or more licensed product			1,333,338
Milestone payments			$ 70,300,000
Funding provided for the research and development under the agreement			$ 2,000,000.0
Commercial Agreement | Clinical Stage Biopharmaceutical Company | Initial License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement execution month and year			2016-02
Commercial Agreement | Clinical Stage Biopharmaceutical Company | Second License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement execution month and year			2019-01
Commercial Agreement | Affiliate of Clinical-Stage Biopharmaceutical Company
Research And Development Arrangement Contract To Perform For Others [Line Items]
Equity payments percentage			20.00%
Common stock, shares issued			291,944		105,277
Common stock fair market value					$ 400,000